Author:
Koh Hock Lye,Teh Su Yean,Noordin Noorliza M.,Sulaiman Lokman H.
Abstract
Objective: Malaysian health ministry is currently evaluating the licensing of dengue vaccine Dengvaxia using a set of criteria including safety, efficacy and cost-effectiveness. The purpose of this research is to formulate a model framework to assist transparent decision-making.Methods: To quantify the cost-effective price of vaccine, pharmacoeconomic evaluation models are commonly used. We review in this paper dengue economic burdens and pharmacoeconomic models, with particular reference to cost-effectiveness.Results: A major weakness in current pharmacoeconomic models is the omission of cost of vaccine production, which is two orders of magnitude lower than the market price. This paper proposes an inclusive model that yields a highly cost-effective threshold price of dengue vaccine at USD 5 per dose for Malaysia.Conclusion: At USD 5 per dose, Dengue vaccine will be fair, Affordable and sustainable.
Publisher
Innovare Academic Sciences Pvt Ltd
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Best Practices in Research for Achieving SDG3 in Two Malaysian Universities;Handbook of Best Practices in Sustainable Development at University Level;2022
2. Pricing model for Dengue vaccine in Malaysia;PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON MATHEMATICAL SCIENCES AND TECHNOLOGY 2020 (MATHTECH 2020): Sustainable Development of Mathematics & Mathematics in Sustainability Revolution;2021
3. Achieving Excellence in Sustainable Development Goals in Sunway University Malaysia;World Sustainability Series;2019-05-01
4. Systematic review of health economic evaluation studies of dengue vaccines;Vaccine;2019-04
5. ASEI-SEIR model with vaccination for dengue control in Shah Alam, Malaysia;AIP Conference Proceedings;2018